NY-THETARAY/NOVATTI
14.9.2022 14:01:56 CEST | Business Wire | Press release
ThetaRay, a leading provider of AI-powered transaction monitoring technology, today announced that Novatti Group (ASX:NOV), a leading fintech that enables businesses to pay and be paid, has chosen SONAR, ThetaRay’s SaaS AML transaction monitoring solution, to protect its growing global payments services against money laundering and other financial crimes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220914005466/en/
Headquartered in Australia, Novatti Group enables businesses and individuals to make payments both domestically and internationally. Novatti currently serves 59 countries with products including cross-border transfers, digital wallets and vouchers, and overseas bill payments.
Novatti is ThetaRay’s first SaaS customer in the Asia-Pacific region.
SONAR, ThetaRay's advanced AI-powered transaction monitoring solution based on “artificial intelligence intuition,” will monitor hundreds of thousands of transactions per year for Novatti. The solution’s ability to detect the earliest signs of sophisticated money laundering activity will enable Novatti to verify that processed transactions are isolated from illegal activity without affecting the quality of service. This ability to provide a trustworthy, secure service will empower Novatti to increase its international growth opportunities.
“As we expand our relationships and add new payment services, we need an AML transaction monitoring solution that is efficient and can keep up with the increasing transaction volumes of our growing business,” said Evangelia Pefkou, Group GM of Risk, Legal and Compliance at Novatti Group. “We chose ThetaRay’s SONAR because it is a true AI-based solution that effectively prevents financial crime – including unknown and hidden money laundering – with high detection rates and low false positives. This will enable us to file high-quality reports proactively and efficiently to regulators.”
“We are excited about the opportunity to help Novatti Group deliver fast, secure payments and build trust through its global network,” said Mark Gazit, CEO of ThetaRay. “SONAR detects even the newest and most sophisticated criminal schemes, so Novatti will be able to simultaneously establish new relationships to grow global business, increase revenues and improve customer service.”
Cross-border transactions often involve a complicated sequence of financial institutions operating across multiple currencies in different countries, creating a challenge for fintechs and banks to have full transparency into final beneficiaries. By providing full visibility across complex, cross-border transaction paths, SONAR helps protect users against the risk of being exploited for money laundering, terrorist financing, human trafficking, and narco-trafficking while empowering partners to increase their volume of transfers.
“Partnering with Novatti will help grow their business while securing services from money laundering and other financial crimes,” said Dan Wollis, Vice President Strategic Accounts, ThetaRay. “There is a great synergy between the companies, driving innovation in the global payments network. We look forward to collaborating and building a strong relationship.”
SONAR is the industry's most advanced financial crime prevention solution for cross-border payments. It enables the rapid discovery of both known and unknown money laundering threats, with a peerless 95% detection rate and up to 99% reduction in false positives compared to rules-based solutions.
To learn more about Novatti Group visit www.novatti.com.
About ThetaRay:
ThetaRay's AI-powered SONAR transaction monitoring solution, based on “artificial intelligence intuition,” allows banks and fintechs to expand their business opportunities and grow revenues through trusted and reliable cross-border payments. The groundbreaking solution also improves customer satisfaction, reduces compliance costs, and increases risk coverage. Financial organizations that rely on highly heterogeneous and complex ecosystems benefit greatly from ThetaRay's unmatchable low false positive and high detection rates.
To learn more about ThetaRay, visit: www.thetaray.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005466/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
